On October 29, 2024 Owkin , the first end-to-end AI biotech company using cutting-edge causal AI to drive precision drug discovery, development and diagnostics, reported MSIntuit CRC v2 1 , a next-generation AI solution (Press release, Owkin, OCT 29, 2024, View Source [SID1234647505]). Designed to transform the detection and treatment of colorectal cancer (CRC), MSIntuit CRC v2 will initially launch as an RUO version in the United States on Roche’s navify Digital Pathology enterprise software.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MSIntuit CRC v2 builds on the success of CE-IVD certified MSIntuit CRC by integrating Owkin’s industry-leading machine learning models with Roche’s unmatched expertise in oncology diagnostics. MSIntuit CRC v2 will now integrate resection and biopsy analysis, addressing a critical need in pathologists’ workflows.
This latest release features a new architecture with advanced machine learning models that significantly improve model performance. It also features enhanced staining techniques, including H&E (hematoxylin and eosin) and HES (hematoxylin, eosin, and saffron), further refining the product’s accuracy and reliability and expanding the solution’s accessibility to more labs.
Meriem Sefta, Owkin’s Chief Diagnostics Officer, said: "We are excited to bring the next innovations of MSIntuit CRC to pathology laboratories, marking a significant advancement in medical diagnostics. This innovation represents our commitment to pushing the boundaries of artificial intelligence in healthcare. By leveraging cutting-edge AI technology, we aim to provide more accurate diagnostic tools that will enable pathologists and oncologists to make more informed decisions. Our goal is to help deliver highly personalized treatment plans, improving patient outcomes and ensuring that each individual receives the most accurate care, tailored to their unique medical needs. This is just the first step in transforming the future of patient care through technology solutions and we look forward to expanding our collaboration with Roche Diagnostics as we pursue this critical mission."
These tools are designed to improve pathology knowledge, enabling cancer patients to benefit from precision medicine and targeted treatments. The RUO version of MSIntuit CRC v2 will soon be available in the United States on Roche’s navify Digital Pathology enterprise software, with additional platforms to come.